Study · Not a test of the peptide alone · 2024

6 results

Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes.

Philis-Tsimikas A, Aroda VR, De Block C, Billings LK, Liebl A, Sivarathinasami R, D'Cruz JM, Lingvay I

Journal of diabetes science and technology29 Jan 2023Cited by 8 (Europe PMC)

PMID36710452PMCIDPMC11089877DOI10.1177/19322968221149041PepBankPUB-36710452

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in DUAL V, IDegLira increased derived time in range more than insulin glargine U100 (ETD 4.18%).
In plain wordsIn adults with type 2 diabetes, the insulin-liraglutide combination raised time in glucose range more than insulin glargine alone in one trial.
Peptide
Liraglutide
Outcome
IncreaseChange in derived time in range (dTIR), DUAL V
Study
n: not reported in source
Comparator
Insulin glargine U100
Outcome group
Glycemic control · Metabolic and weight
Measurements
ETD dTIR
4.18%
DUAL V
Source sentences
Summary
ETDs for change from baseline to EOT in dTIR were significantly greater with IDegLira versus glargine U100 in DUAL V (4.18%, P = .027) and DUAL VIII (5.17%, P = .001).
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis of the DUAL V and DUAL VIII trials aimed to compare dTIR with an insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus insulin glargine 100 units/mL (glargine U100) in people with type 2 diabetes (T2D).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3671045201
02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes in DUAL VIII, IDegLira increased derived time in range more than insulin glargine U100 (ETD 5.17%).
In plain wordsIn adults with type 2 diabetes, the insulin-liraglutide combination raised time in glucose range more than insulin glargine alone in a second trial.
Peptide
Liraglutide
Outcome
IncreaseChange in derived time in range (dTIR), DUAL VIII
Study
n: not reported in source
Comparator
Insulin glargine U100
Outcome group
Glycemic control · Metabolic and weight
Measurements
ETD dTIR
5.17%
DUAL VIII
Source sentences
Summary
ETDs for change from baseline to EOT in dTIR were significantly greater with IDegLira versus glargine U100 in DUAL V (4.18%, P = .027) and DUAL VIII (5.17%, P = .001).
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis of the DUAL V and DUAL VIII trials aimed to compare dTIR with an insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus insulin glargine 100 units/mL (glargine U100) in people with type 2 diabetes (T2D).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3671045202
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In DUAL V, the proportion with at least 70% dTIR was similar with IDegLira (62%) and glargine U100 (60%).
In plain wordsIn one trial, about the same share of people reached 70% time in range with the combination (62%) as with glargine alone (60%).
Peptide
Liraglutide
Outcome
No significant changeProportion with at least 70% dTIR at end of trial, DUAL V
Study
n: not reported in source
Comparator
Insulin glargine U100
Outcome group
Glycemic control · Metabolic and weight
Measurements
Proportion >=70% dTIR
62%
IDegLira, DUAL V
Proportion >=70% dTIR
60%
glargine U100, DUAL V
Source sentences
Summary
The proportions of people achieving ≥70% dTIR at EOT with IDegLira and glargine U100, respectively, were 62% and 60% in DUAL V (P = .7541), and 50% and 26% in DUAL VIII (P < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis of the DUAL V and DUAL VIII trials aimed to compare dTIR with an insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus insulin glargine 100 units/mL (glargine U100) in people with type 2 diabetes (T2D).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3671045203
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In DUAL VIII, more people reached at least 70% dTIR with IDegLira (50%) than with glargine U100 (26%).
In plain wordsIn a second trial, more people reached 70% time in range with the combination (50%) than with glargine alone (26%).
Peptide
Liraglutide
Outcome
IncreaseProportion with at least 70% dTIR at end of trial, DUAL VIII
Study
n: not reported in source
Comparator
Insulin glargine U100
Outcome group
Glycemic control · Metabolic and weight
Measurements
Proportion >=70% dTIR
50%
IDegLira, DUAL VIII
Proportion >=70% dTIR
26%
glargine U100, DUAL VIII
Source sentences
Summary
The proportions of people achieving ≥70% dTIR at EOT with IDegLira and glargine U100, respectively, were 62% and 60% in DUAL V (P = .7541), and 50% and 26% in DUAL VIII (P < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis of the DUAL V and DUAL VIII trials aimed to compare dTIR with an insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus insulin glargine 100 units/mL (glargine U100) in people with type 2 diabetes (T2D).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3671045204
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In DUAL V, the proportion with a dTIR increase of at least 5% was 63% in both the IDegLira and glargine U100 groups.
In plain wordsIn one trial, the same share of people (63%) improved time in range by 5% with the combination and with glargine alone.
Peptide
Liraglutide
Outcome
No significant changeProportion with at least 5% increase in dTIR, DUAL V
Study
n: not reported in source
Comparator
Insulin glargine U100
Outcome group
Glycemic control · Metabolic and weight
Measurements
Proportion >=5% dTIR increase
63%
both groups, DUAL V
Source sentences
Summary
The proportion achieving a ≥5% increase in dTIR from baseline to EOT with IDegLira and glargine U100 was 63% in both groups in DUAL V (P = .9043), and 44% and 25%, respectively, in DUAL VIII (P < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis of the DUAL V and DUAL VIII trials aimed to compare dTIR with an insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus insulin glargine 100 units/mL (glargine U100) in people with type 2 diabetes (T2D).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3671045205
06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In DUAL VIII, more people had a dTIR increase of at least 5% with IDegLira (44%) than with glargine U100 (25%).
In plain wordsIn a second trial, more people improved time in range by 5% with the combination (44%) than with glargine alone (25%).
Peptide
Liraglutide
Outcome
IncreaseProportion with at least 5% increase in dTIR, DUAL VIII
Study
n: not reported in source
Comparator
Insulin glargine U100
Outcome group
Glycemic control · Metabolic and weight
Measurements
Proportion >=5% dTIR increase
44%
IDegLira, DUAL VIII
Proportion >=5% dTIR increase
25%
glargine U100, DUAL VIII
Source sentences
Summary
The proportion achieving a ≥5% increase in dTIR from baseline to EOT with IDegLira and glargine U100 was 63% in both groups in DUAL V (P = .9043), and 44% and 25%, respectively, in DUAL VIII (P < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
This post hoc analysis of the DUAL V and DUAL VIII trials aimed to compare dTIR with an insulin degludec/liraglutide fixed-ratio combination (IDegLira) versus insulin glargine 100 units/mL (glargine U100) in people with type 2 diabetes (T2D).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3671045206

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02501161

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/Sn = 1,01231 Jan 2016 to 3 Oct 2018

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 27 Nov 2019

CompletedPhase 3Results postedNCT01952145

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/Sn = 55720 Sept 2013 to 4 Nov 2014

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 3 Jan 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.